Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence
Anke Post, Trevor S. Smart, Kimberley Jackson, Joanne Mann, Richard Mohs, Linda Rorick-Kehn, Michael Statnick, Raymond Anton, Stephanie S. O'Malley and Conrad J. Wong
Version of Record online: 20 JUL 2016 | DOI: 10.1111/acer.13147
This was a proof-of-concept study to evaluate the efficacy of LY2940094, a nociceptin/orphanin FQ peptide receptor antagonist, in reducing alcohol consumption in actively alcohol-drinking patients with alcohol dependence. Although not reducing the number of drinks per day, LY2940094, compared to placebo, did reduce heavy drinking days and increased abstinence days in patients with alcohol dependence.